Aurinia Pharmaceuticals AUPH Finite Lived Intangible Assets - Gross
Finite Lived Intangible Assets - Gross at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's finite lived intangible assets - gross.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's finite lived intangible assets - gross?
- Aurinia Pharmaceuticals (AUPH) reported finite lived intangible assets - gross of $20.42M in Q1 2026.
- How has Aurinia Pharmaceuticals's finite lived intangible assets - gross changed year-over-year?
- Aurinia Pharmaceuticals's finite lived intangible assets - gross increased by 1.4% year-over-year, from $20.14M to $20.42M.
- What is the long-term trend for Aurinia Pharmaceuticals's finite lived intangible assets - gross?
- Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's finite lived intangible assets - gross has grown at a 2.0% compound annual growth rate (CAGR), from $18.45M to $20.38M.
- What does finite lived intangible assets - gross mean?
- This metric tracks the total historical cost of intangible assets that have a defined useful life, such as patents, software licenses, or customer relationships. It excludes assets with indefinite lives like certain trademarks or goodwill. It is a key indicator of the company's investment in intellectual property and intangible competitive advantages.